All News
Filter News
Found 44 articles
-
Acepodia Publishes Preclinical Data on Novel Off-the-Shelf Natural Killer Cell Therapy, ACE1702, for HER2-Expressing Solid Tumors Using Antibody-Cell Conjugation Technology in the Journal Cancers
6/7/2021
Acepodia, today announced that an article describing the efficacy profile of ACE1702, Acepodia’s novel, off-the-shelf natural killer (NK) cell therapy against HER2-expressing solid tumors, was published in the journal Cancers.
-
Acepodia Presents Data on its Allogeneic Natural Killer-Like Gamma-Delta T Cell Therapy, ACE1831, in Development for Hematological Cancers
5/19/2021
Preclinical data demonstrate potential of off-the-shelf, NK-like gamma-delta T cells in developing cell therapies for the treatment of cancers ACE1831, an allogeneic cell therapy candidate targeting hematological cancers, demonstrates prolonged survival in vivo
-
Acepodia Appoints Thorsten Graef, M.D., Ph.D., as Chief Medical Officer and Michael Brock as Chief Strategy OfficerKey executive hires strengthen Acepodia’s expanding leadership team and position the company for upcoming growth catalysts
5/11/2021
Acepodia, a biotechnology company developing next generation solid tumor and hematologic cancer cell therapies, announced the appointments of Thorsten Graef, M.D., Ph.D., as chief medical officer and Michael Brock as chief strategy officer.
-
Acepodia CEO and Co-founder, Sonny Hsiao, Ph.D., to Present at Allogeneic Cell Therapies Summit 2021
5/10/2021
Acepodia , a biotechnology company developing next generation solid tumor and hematologic cancer cell therapies, today announced that Sonny Hsiao, Ph.D., chief executive officer and co-founder of Acepodia, has been invited to speak at the Allogeneic Cell Therapies Summit 2021 taking place virtually May 17-19, 2021.
-
Days after announcing the U.S. Food and Drug Administration (FDA) has cleared the next clinical trials to launch for its lead natural killer (NK) cell therapies, NKMax America announced it has renamed itself NKGen Biotech.
-
BioSpace Movers & Shakers, March 26
3/26/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Acepodia Appoints Jimmy Lai as Chief Financial Officer
3/23/2021
Acepodia, a biotechnology company developing next generation solid tumor and hematologic cancer cell therapies, today announced the appointment of Jimmy Lai as chief financial officer.
-
Acepodia to Present at the 6th Annual Innate Killer Summit
3/18/2021
Acepodia, a biotechnology company developing next generation solid tumor and hematologic cancer cell therapies, today announced that Sonny Hsiao, Ph.D., chief exectuvie officer and co-founder of Acepodia will deliver a keynote clinical data presentation of preclinical and interim clinical data from studies of the Company’s lead clinical natural killer (NK) cell therapy candidate, ACE1702, during the virtual 6 th Annual Innate Killer Summit
-
Yesterday marked the close of three new financing rounds in the biotech space. Although none of today’s are that large, there is still plenty of money on the move. Here’s a look.
-
Acepodia Completes $47 Million Series B Financing to Advance Pipeline of Allogeneic Cell Therapy CandidatesPrograms receiving funding include those developing company’s proprietary cryopreserved NK and gamma delta T-cell candidates
3/16/2021
Acepodia, a biotechnology company developing next generation solid tumor and hematologic cancer cell therapies, today announced the closing of its $47 million Series B financing.
-
Biopharma Executive Perspectives on 2021
1/11/2021
The lessons learned from the global pandemic are expected to translate to existing and emerging therapeutic areas - particularly oncology; more efficient regulatory-industry relationships; mRNA is a word we will continue to hear a lot about; and home health care is here to stay. -
Acepodia to Present Late-breaking Poster Presentation Supporting the Potential of its NK Cell Therapy in Solid Tumors at The Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting
11/9/2020
ACE1702 demonstrates enhanced cytotoxicity against multiple HER2-expressing cell lines and activity under immunosuppressive conditions
-
Acepodia to Deliver Late-breaking Poster Presentation at The Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting
11/2/2020
Acepodia, a biotechnology company developing novel off-the-shelf cell therapies against solid-tumor and hematologic cancers, today announced that Howard Li, Ph.D., Preclinical Research Scientist, will present a late-breaking virtual poster at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting.
-
Acepodia to Present at the 7th Annual China Healthcare Summit
10/22/2020
Acepodia, a biotechnology company developing novel off-the-shelf cell therapies against solid-tumor and hematologic cancers, today announced that Sonny Hsiao, Ph.D., chief executive officer, will present a corporate overview at the upcoming 7th Annual China Healthcare Summit on November 9, 2020. The presentation will outline the progress of Acepodia’s Phase 1 clinical trial of lead candidate ACE1702, a unique natural killer (N
-
BioSpace Movers & Shakers, Sept. 4
9/4/2020
Biopharma and life science companies from across the globe strengthen their leadership teams and boards with these Movers & Shakers. -
Acepodia Strengthens Management Team with Appointments of Biotech Industry VeteransDoctors Mark Gilbert and Joe McCracken appointed to senior positions
9/1/2020
Acepodia, a biotechnology company developing next generation solid tumor and blood-based cancer cell therapies, today announced key appointments to its business and clinical development teams. Mark J. Gilbert, M.D., a cell therapy pioneer, joins as senior vice president of Research and Development and will lead early-stage research efforts to advance the company’s proprietary, potent and off-the-shelf cell therapies from exploratory development stages into clinical trials.
-
Acepodia Initiates a Phase 1 Clinical Trial Evaluating Allogeneic NK Cell Therapy ACE1702 for Treatment of Solid Tumors
8/18/2020
• ACE1702 is the first antibody-conjugated NK cell therapy in clinical development for the treatment of HER2-expressing solid tumors • Clinical trial expected to enroll up to 24 patients across the U.S. SAN FRANCISCO and TAIPEI, Taiwan, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Acepodia, a biotechnology company developing novel off-the-shelf cell therapies against solid-tumor and hematologic cancers, today announced that it has dosed the first patient in its Phase 1 open-label, dose escalatio
-
Acepodia to Present at the Inaugural LifeSci Partners Private Company Virtual Summer Symposium
7/29/2020
Acepodia, a biotechnology company developing cancer immunotherapies based on its novel Antibody-Cell Conjugation (ACC) and off-the-shelf NK (oNK) technology today announced it will participate in the LifeSci Partners Private Company Virtual Summer Symposium, taking place August 4-5, 2020. The company will deliver a corporate update to potential investors and strategic partners among other various relevant audiences. The corpor
-
BioSpace Global Roundup, July 16
7/16/2020
Biopharma and life sciences companies from across the globe provide updates on their business and pipelines. -
Acepodia and JW Therapeutics Enter into Option and License Agreement for Off-the-shelf NK Cell Therapies
7/14/2020
JW therapeutics to receive exclusive licenses to develop and commercialize ACE1702 and ACE1655 in Mainland China , Hong Kong, and Macau Acepodia to receive upfront and milestone payments in addition to royalties on sales SAN FRANCISCO and TAIPEI, Taiwan, July 14, 2020 (GLOBE NEWSWIRE) -- Acepodia, a biotechnology company developing cancer immunotherapies based on its novel Antibody-Cell Conjugation (ACC) technology platform and JW Therapeutics, a biotechnology company focusing on the